ubiquitin specific peptidase 9 Y-linkedGenealiases: DFFRY · FAF-Y · SPGFY2
Q-omics provides the consensus-scored USP9Y profile across patient tissues and cancer cell-line models. USP9Y expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, USP9Y is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, USP9Y RNA expression shows 10,133 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRP, and TGCT as cancer lineages where USP9Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP9Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP9Y survival associations across molecular data types. USP9Y RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP9Y RNA expression–survival associations across cancer types. High USP9Y expression shows unfavorable associations in THCA, LUAD, MESO and UCEC, but favorable associations in HNSC and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for USP9Y RNA expression.
This table summarizes USP9Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for USP9Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP9Y shows lower tumor expression in KIRP, KICH, HNSC and KIRC and higher tumor expression in PRAD and CHOL. The KIRP box plot shows higher USP9Y RNA expression in normal versus tumor tissue (log2 FC = −2.049, t-test p < 0.001).
This table shows molecular features associated with USP9Y in patient tissues and cancer cell lines. In patient samples, USP9Y shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, USP9Y RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
